journal article·2014-04Open access

Bitargeting and ambushing nanotheranostics

Rıdvan Say, Lokman Uzun, Suzan Yazar, Adil Denizli, Deniz Hür, Filiz Yılmaz, Arzu Ersöz

Abstract

The main problem in cancer chemotherapy is the cytotoxic side effects of therapeutics on healthy tissues and cells. The targeted drug delivery and nanotechnology are intensively investigated area to find new ways to solve, at least to reduce, these problems. Hereby, we have reported a new method inspired from both conventional military strategies and biorecognition in the body. In this respect, we have produced two fluorescent nano-drug systems with bitargeting and biorecognition properties, recognizing cancer cells and each other. The multiplexed nanostructures were interacted with HL-60 cells to show their efficiency for bitargeting, ambushing, timed, and double-controlled cancer cell apoptosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. 10.1016/j.biomaterials.2009.07.00810.1016/j.biomaterials.2009.07.008 ↗
2. Baldwin A · Arch Biochem Biophys · 2003 · 409 · 19710.1016/S0003-9861(02)00453-8 ↗
3. Byrne JD · Adv Drug Del Rev · 2008 · 20 · 161510.1016/j.addr.2008.08.005 ↗
4. 10.1124/mol.65.5.127810.1124/mol.65.5.1278 ↗
5. Chen L · Cancer Res · 1997 · 57 · 4830
6. Chen ZG · Trends Mol Med · 2010 · 16 · 59410.1016/j.molmed.2010.08.001 ↗
7. Davis ME · Mol Pharmaceutics · 2009 · 6 · 65910.1021/mp900015y ↗
8. Diltemiz SE · Talanta · 2008 · 75 · 89010.1016/j.talanta.2007.12.036 ↗
9. Dobrovolskaia MA · Mol Pharmaceutics · 2008 · 5 · 48710.1021/mp800032f ↗
10. 10.1111/j.1749-6632.1993.tb17204.x10.1111/j.1749-6632.1993.tb17204.x ↗
11. Gewin V · Nature · 2009 · 460 · 54010.1038/nj7254-540a ↗
12. Grainger SJ · Mol Pharmaceutics · 2010 · 7 · 200610.1021/mp100280b ↗
13. Gültekin A · Talanta · 2009 · 78 · 133210.1016/j.talanta.2009.02.007 ↗
14. Jounaidi Y · Cancer Res · 2000 · 60 · 3761
15. Jounaidi Y · Cancer Res · 2001 · 61 · 4437
16. 10.1158/0008-5472.CAN-03-179810.1158/0008-5472.CAN-03-1798 ↗
17. Komatsu T · Drug Metabol Dispos · 2000 · 28 · 1457
18. Kumar S · J Biol Chem · 2005 · 280 · 1956910.1074/jbc.M500158200 ↗
19. Liang M · Bioconjugate Chem · 2010 · 21 · 138510.1021/bc100081h ↗
20. Liu HY · Bioconjugate Chem · 2011 · 22 · 51010.1021/bc200004z ↗
21. McFadyen MCE · Mol Cancer Ther · 2004 · 3 · 36310.1158/1535-7163.363.3.3 ↗
22. 10.1016/j.jconrel.2009.03.01010.1016/j.jconrel.2009.03.010 ↗
23. Mo Y · J Control Release · 2005 · 108 · 24410.1016/j.jconrel.2005.08.013 ↗
24. Park H · Prog Polym Sci · 2008 · 33 · 11310.1016/j.progpolymsci.2007.09.003 ↗
25. Patra CR · Adv Drug Del Rev · 2010 · 62 · 34610.1016/j.addr.2009.11.007 ↗
26. Peterson JA · J Biol Chem · 1976 · 251 · 401010.1016/S0021-9258(17)33349-5 ↗
27. Roy A · Mol Pharmaceutics · 2010 · 7 · 177810.1021/mp100153r ↗
28. Say R · Histochem Cell Biol · 2011 · 135 · 52310.1007/s00418-011-0801-7 ↗
29. Say R · PCT/IB2009/055707, Applied 11 Dec · 2009
30. Schmidt R · British J Cancer · 2004 · 90 · 91110.1038/sj.bjc.6601492 ↗
31. 10.1038/sj.cgt.770060110.1038/sj.cgt.7700601 ↗
32. Werlin R · Nature Nanotechnol · 2011 · 6 · 6510.1038/nnano.2010.251 ↗
33. Wu PC · Bioconjugate Chem · 2008 · 19 · 197210.1021/bc800092w ↗